Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

PubWeight™: 3.34‹?› | Rank: Top 1%

🔗 View Article (PMID 4254940)

Published in J Neurochem on June 01, 1971

Authors

D G Grahame-Smith

Articles citing this

Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90

Effects on plasma and brain tryptophan in the rat of drugs and hormones that influence the concentration of unesterified fatty acid in the plasma. Br J Pharmacol (1974) 1.68

Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48

The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol (1978) 1.48

Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38

The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol (2002) 1.37

The acute effects of oral (--)-tryptophan in human subjects. Br J Clin Pharmacol (1975) 1.23

Role of tryptaminergic mechanisms in the elements of the behavioural syndrome evoked by tryptophan and a monoamine oxidase inhibitor [proceedings]. Br J Pharmacol (1977) 1.22

Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) (2004) 1.22

Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol (1980) 1.11

A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors. Br J Pharmacol (1972) 1.10

Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol (1977) 1.10

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology (2011) 1.06

Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-DOPA. Br J Pharmacol (1976) 1.05

Effect of tryptophan administration on tryptophan, 5-hydroxyindoleacetic acid and indoleacetic acid in human lumbar and cisternal cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1981) 1.03

Neuropharmacology of 5-hydroxytryptamine. Br J Pharmacol (2006) 0.99

The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol (2010) 0.96

A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure-activity requirements for the agonists. Br J Pharmacol (1981) 0.95

Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-l-tryptophan in clorgyline-pretreated rats. Eur J Pharmacol (2008) 0.94

Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci (1992) 0.91

Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol (1990) 0.91

Metabolism of an oral tryptophan load by women and evidence against the induction of tryptophan pyrrolase by oral contraceptives. Br J Clin Pharmacol (1978) 0.90

Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol (1990) 0.90

beta-Adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine. Br J Pharmacol (1978) 0.90

A comparison of an improved o-phthalaldehyde fluorometric method and high pressure liquid chromatography in the determination of brain 5-hydroxyindoles of rats treated with L-tryptophan and p-chlorophenyl-alanine. Br J Pharmacol (1981) 0.89

Effects of 8-OHDPAT and 5-HT1A antagonists WAY100135 and WAY100635, on guinea-pig behaviour and dorsal raphe 5-HT neurone firing. Br J Pharmacol (1996) 0.89

An in vivo dialysis and behavioural study of the release of 5-HT by p-chloroamphetamine in reserpine-treated rats. Br J Pharmacol (1989) 0.88

Cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid: reciprocal relationships with impulsive aggression in human subjects. J Neural Transm (Vienna) (2010) 0.87

Ingestion of branched-chain amino acids and tryptophan during sustained exercise in man: failure to affect performance. J Physiol (1995) 0.86

Central effects of clonidine 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride in fowls. Br J Pharmacol (1975) 0.85

On the role of central nervous system catecholamines and 5-hydroxytryptamine in the nialamide-induced behavioural syndrome. Br J Pharmacol (1972) 0.85

The influence of L-tryptophan and monoamine oxidase inhibitors on catecholamine metabolism in rat brain. Br J Pharmacol (1978) 0.85

Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK. Br J Pharmacol (2008) 0.84

Diminished serotonin uptake in platelets of transgenic mice with increased Cu/Zn-superoxide dismutase activity. EMBO J (1989) 0.84

Labelled alpha-methyl-L-tryptophan as a tracer for the study of the brain serotonergic system. J Psychiatry Neurosci (2001) 0.84

Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blocker. Br J Pharmacol (1983) 0.83

Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners. J Neural Transm (Vienna) (1997) 0.82

beta-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses. Br J Pharmacol (1982) 0.82

Behavioural changes induced by N,N-dimethyl-tryptamine in rodents. Br J Pharmacol (1980) 0.82

Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome. Eur J Pharmacol (2009) 0.82

Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci (1997) 0.82

Relationship between extracellular 5-hydroxytryptamine and behaviour following monoamine oxidase inhibition and L-tryptophan. Br J Pharmacol (1988) 0.81

Increased total activity in the rat after L-tryptophan plus the monoamine oxidase-A inhibitor amiflamine but not after L-tryptophan plus clorgyline. Br J Pharmacol (1985) 0.81

Increased central 5-hydroxytryptamine receptor mechanisms in rats after chronic neuroleptic treatment. Br J Pharmacol (1981) 0.80

The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. Br J Pharmacol (2005) 0.80

Repeated chlorpromazine administration increases a behavioural response of rats to 5-hydroxytryptamine receptor stimulation. Br J Pharmacol (1977) 0.79

Functional changes in cerebral 5-hydroxytryptamine metabolism in the mouse induced by anticonvulsant drugs. Br J Pharmacol (1978) 0.79

Changes in extracellular 5-HIAA concentrations as measured by in vivo microdialysis technique in relation to changes in 5-HT release. Psychopharmacology (Berl) (2004) 0.78

Proceedings: The role of brain dopamine in the hyperactivity syndrome produced in rats after administration of L-tryptophan and a monoamine oxidase inhibitor. Br J Pharmacol (1974) 0.78

A pharmacological analysis of the hyperactivity syndrome induced by beta-phenylethylamine in the mouse. Br J Pharmacol (1982) 0.77

Monoaminergic involvement in the pharmacological actions of buspirone. Br J Pharmacol (1985) 0.77

Interaction in the cerebral metabolism of the biogenic amines. Effects of phenelzine on the cerebral metabolism of the 5-hydroxyindoles in dog brain. Br J Pharmacol (1972) 0.75

Some observations on the behavioural and biochemical effects of L-tryptophan plus a monoamine oxidase inhibitor in immature rats [proceedings]. Br J Pharmacol (1979) 0.75

David Grahame Grahame-Smith: clinical pharmacologist. 1933-2011. Br J Clin Pharmacol (2012) 0.75

The 'wet dog shake" behaviour in the rat and 5-hydroxytryptamine [proceedings]. Br J Pharmacol (1977) 0.75

Editorial: Tryptophan and depression. Br Med J (1976) 0.75

Repeated exposure of rats to the convulsant agent flurothyl enhances 5-hydroxytryptamine- and dopamine-mediated behavioural responses. Br J Pharmacol (1978) 0.75

Role of tryptamine in the behavioural changes caused by a monoamine oxidase inhibitor and L-tryptophan [proceedings]. Br J Pharmacol (1977) 0.75

Interaction in the cerebral metabolism of the biogenic amines. Effect of phenelzine on this interaction. Br J Pharmacol (1972) 0.75

Articles by these authors

(truncated to the top 100)

Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50

Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03

Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49

Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08

Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07

Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03

Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90

Misuse of temazepam. BMJ (1991) 1.82

Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77

Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56

Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48

Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44

Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38

The prevention by inhibitors of brain proptein synthesis of the hyperactivity and hyperpyrexia produced in rats by monoamine oxidase inhibition and the administration of L-tryptophan or 5-methoxy-N,N-dimethyltryptamine. J Neurochem (1972) 1.35

Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35

5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol (1989) 1.35

Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35

Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med (1978) 1.34

Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34

Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31

Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry (1975) 1.28

The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26

(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26

Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol (1979) 1.23

The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy. Br J Clin Pharmacol (1979) 1.20

A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma. Br J Clin Pharmacol (1977) 1.17

The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer (1994) 1.15

A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine. J Auton Pharmacol (1983) 1.15

The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13

The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13

Psittacosis masquerading as rheumatic fever. Br Med J (1978) 1.12

Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12

The relationship between plasma catecholamines and severity of injury in man. J Trauma (1984) 1.11

Abnormal regulation of adenosine 3',5'-monophosphate and corticosterone formation in an adrenocortical carcinoma. J Clin Invest (1969) 1.11

Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11

Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10

The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br J Clin Pharmacol (1979) 1.10

Plasma adrenaline and noradrenaline concentrations and dopamine-beta-hydroxylase activity in myocardial infarction with and without cardiogenic shock. Br Heart J (1979) 1.10

Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol (1978) 1.10

The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes after incubation for 3 days. Br J Clin Pharmacol (1986) 1.07

The contrasting actions of TRH and cycloheximide in altering the effects of centrally acting drugs: evidence for the non-involvement of dopamine sensitive adenylate cyclase. Neuropharmacology (1976) 1.05

Tryptophan hydroxylation in brain. Biochem Biophys Res Commun (1964) 1.04

The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects. Biochem J (1972) 1.04

Evidence for the presence of a vasoactive substance (possibly involved in the aetiology of cerebral arterial spasm) in cerebrospinal fluid from patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (1976) 1.04

The biosynthesis of 5-hydroxytryptamine in brain. Biochem J (1967) 1.03

Altered distribution of digoxin in renal failure--a cause of digoxin toxicity? Br J Clin Pharmacol (1976) 1.03

The carcinoid syndrome. Am J Cardiol (1968) 1.00

TRH potentiates behavioural changes following increased brain 5-hydroxytryptamine accumulation in rats. Nature (1974) 0.99

Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med (1979) 0.98

Cation transport abnormalities in vivo in untreated essential hypertension. Clin Sci (Lond) (1986) 0.98

A method for the study of cation transport in vivo: effects of digoxin administration and of chronic renal failure on the disposition of an oral load of rubidium chloride. Clin Sci (Lond) (1984) 0.97

The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmacol (1981) 0.97

Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. Gut (1981) 0.96

Changes in platelet alpha 2-adrenoceptor binding post partum: possible relation to maternity blues. Lancet (1983) 0.96

BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology (1993) 0.96

Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694). Brain Res (1991) 0.95

Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution. Br J Clin Pharmacol (1977) 0.95

In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. J Neurochem (1989) 0.94

Evidence for an altered mode of action of the sodium-lithium countertransporter in vivo in patients with untreated essential hypertension. J Hypertens (1993) 0.94

Monitoring digoxin therapy. The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. Q J Med (1978) 0.94

Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol (1979) 0.93

Effect of oral contraceptives on platelet noradrenaline and5-hydroxytryptamine receptors and aggregation. Lancet (1979) 0.93

Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-Dopa. Psychopharmacology (Berl) (1976) 0.93

Repeated electroconvulsive shock extends the duration of enhanced gene expression for BDNF in rat brain compared with a single administration. Brain Res Mol Brain Res (1998) 0.92

Clinical academic medicine: a Socratic dialogue. BMJ (1997) 0.92

The binding characteristics of [3H]-dihydroergocryptine on intact human platelets. Br J Pharmacol (1982) 0.92

Treatment of the carcinoid syndrome by local removal of hepatic metastases. Proc R Soc Med (1972) 0.91

Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol (1990) 0.91

Tryptophan transport across the synaptosomal membrane. J Neurochem (1970) 0.91

Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret. Neuroscience (1990) 0.91

The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology (Berl) (1990) 0.90

Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties. Br J Clin Pharmacol (1975) 0.89

The biosynthesis of 5-hydroxytryptamine in carcinoid tumours and intestine. Clin Sci (1967) 0.89

Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br J Pharmacol (1989) 0.89

Pharmacological blockade of carcinoid flushing provoked by catecholamines and alcohol. Lancet (1969) 0.89

The effects of iron deficiency on brain biogenic monoamine biochemistry and function in rats. Neuropharmacology (1980) 0.88

Human platelet monoamine oxidase activity in iron-deficiency anaemia. Clin Sci Mol Med (1975) 0.88

A sensitive high-temperature electrothermal atomic absorption analysis for Rb+ in erythrocytes and plasma of normal and hypertensive persons. Clin Chem (1985) 0.87

In vivo cation transport during short-term and long-term digoxin therapy. Br J Clin Pharmacol (1986) 0.87

Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378. Eur J Pharmacol (1990) 0.87

The effect of chronic antidepressant administration on beta-adrenoceptor function of the rat pineal. Br J Pharmacol (1983) 0.87

Penetration of C14-labelled rifampicin into primate peripheral nerve. Experientia (1975) 0.86

Release of endogenous 5-hydroxytryptamine in rat ventral hippocampus evoked by electrical stimulation of the dorsal raphe nucleus as detected by microdialysis: sensitivity to tetrodotoxin, calcium and calcium antagonists. Neuroscience (1990) 0.86

Unchanged rate of brain serotonin synthesis during chronic morphine treatment and failure of parachlorophenylalanine to attenuate withdrawal syndrome in mice. Nature (1970) 0.85

Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex. J Neurochem (1989) 0.85

Bioavailability of digoxin. Lancet (1972) 0.85

5-HT1A and 5-HT2 receptors differentially regulate the excitability of 5-HT-containing neurones of the guinea pig dorsal raphe nucleus in vitro. Brain Res (2001) 0.84

5-HT3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur J Pharmacol (1993) 0.84

Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own erythrocytes during glycoside therapy. Klin Wochenschr (1981) 0.84

Academic pursuits in clinical pharmacology. Research emphasis. Clin Pharmacol Ther (1986) 0.84

Neuroendocrine effects of azapirones. J Clin Psychopharmacol (1990) 0.84

Repeated administration of subconvulsant doses of GABA antagonist drugs. I. Effect on seizure threshold (kindling). Psychopharmacology (Berl) (1982) 0.84

Influence of thyroid hormone on 5-HT(1A) and 5-HT(2A) receptor-mediated regulation of hippocampal BDNF mRNA expression. Neuropharmacology (2001) 0.83

Inhibition of adenyl cyclase by an exotoxin of Bacillus thuringiensis. Nature (1975) 0.83

Localization of 5-HT3 receptor binding sites in human dorsal vagal complex. Eur J Pharmacol (1989) 0.83

The effect of lithium on 5-HT-mediated neuroendocrine responses and platelet 5-HT receptors. Psychopharmacology (Berl) (1986) 0.83

Action of adenosine receptor antagonists on hypoxia-induced effects in the rat hippocampus in vitro. Br J Pharmacol (1995) 0.82

beta-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses. Br J Pharmacol (1982) 0.82

Clinical pharmacology. Adverse drug interactions. Br Med J (Clin Res Ed) (1981) 0.82

Serotonergic regulation of mRNA expression of Arc, an immediate early gene selectively localized at neuronal dendrites. Neuropharmacology (2000) 0.82